Table 2.
Healthcare utilization and costs per-patient (eribulin vs. capecitabine).
| Eribulin |
Capecitabine |
p value | |||||||
|---|---|---|---|---|---|---|---|---|---|
| N | Median | Mean | 95%CI | N | Median | Mean | 95%CI | ||
| Healthcare utilization | |||||||||
| Outpatient oncology visits (n) | 278 | 17.0 | 28.4 | 24.8–32.0 | 281 | 23.0 | 38.8 | 33.6–43.9 | 0.049 |
| Emergency room visits (n) | 85 | 1.0 | 2.0 | 1.6–2.4 | 73 | 1.0 | 2.3 | 1.8–2.8 | 0.68 |
| Hospitalizations (n) | 160 | 2.0 | 4.3 | 3.3–5.3 | 157 | 2.0 | 3.6 | 2.8–4.4 | 0.40 |
| Days of hospitalization (n) | 160 | 13.0 | 32.8 | 23.0–42.6 | 157 | 14.0 | 36.8 | 10.6–63.0 | 0.64 |
| Medication cost | |||||||||
| Cost of eribulin/capecitabine | 298 | 254,300.0 | 350,458.6 | 312,554.0–388,363.2 | 298 | 46,144.0 | 76,247.7 | 66,776.6–85,718.8 | <0.0001 |
| Cost of G-CSF | 298 | 0.0 | 16,899.6 | 12,897.0–20,902.3 | 298 | 0.0 | 2313.8 | 1217.3–3410.3 | <0.0001 |
| Total medication cost | 298 | 305,335.0 | 438,335.8 | 388,488.1–488,183.5 | 298 | 154,731.0 | 348,438.4 | 294,184.5–402,692.3 | <0.0001 |
| Medical cost | |||||||||
| Cost of outpatient oncology visits | 298 | 262,319.0 | 405,654.1 | 353,578.1–457,730.1 | 298 | 181,910.5 | 371,177.7 | 313,071.4–429,284.0 | 0.003 |
| Cost of emergency room visits | 298 | 0.0 | 2880.2 | 2055.9–3704.5 | 298 | 0.0 | 2865.3 | 1490.8–4239.9 | 0.18 |
| Cost of hospitalizations | 298 | 25,524.5 | 171,989.5 | 125,334.7–218,644.3 | 298 | 11,733.5 | 123,180.8 | 95,876.9–150,484.7 | 0.45 |
| Total medical cost | 298 | 367,653.0 | 580,523.8 | 514,217.1–646,830.4 | 298 | 282,622.5 | 497,223.8 | 431,400.1–563,047.6 | <0.0001 |
G-CSF granulocyte-colony stimulating factor.